RA101495, A Subcutaneously Administered Peptide Inhibitor of ComplementComponent 5 (C5) for the Treatment of Generalized Myasthenia Gravis(gMG): Phase 1 Results and Phase 2 Design

Journal article

Peer reviewed

James F. Howard, Henry J. Kaminski, Richard J. Nowak, Gil I. Wolfe, Michael G. Benatar, Alonso Ricardo and Michelle Hoarty

NEUROLOGY, Vol.90(15)

2018

Metrics

1 Record Views

Title: RA101495, A Subcutaneously Administered Peptide Inhibitor of ComplementComponent 5 (C5) for the Treatment of Generalized Myasthenia Gravis(gMG): Phase 1 Results and Phase 2 Design
Creators: James F. Howard
Henry J. Kaminski
Richard J. Nowak
Gil I. Wolfe
Michael G. Benatar
Alonso Ricardo
Michelle Hoarty
Publication Details: NEUROLOGY, Vol.90(15)
Publisher: LIPPINCOTT WILLIAMS & WILKINS; TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
Comment: 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los Angeles, CA, APR 21-27, 2018
Academic Unit: Miller School of Medicine; UMMG Department of Neurology; UMMG Dept of Neurology - Neuromuscular Disorders Div
Language: English
Resource Type: Journal article
Record Identifier: 991032830845702976